Active/Enrolling:
EGL-SCABP
- Principal Investigator: Nicole Iovine, MD, PhD
- Link: https://clinicaltrials.gov/study/NCT05776004
- Purpose: Pneumonia is an infection in the lungs that can cause mild to severe illness. Severe Community-Acquired Bacterial Pneumonia (SCABP), the focus of this study, is a type of pneumonia that is life-threatening and acquired in the community. Patients may experience severe respiratory symptoms and often require ICU admission. The goal of SCABP is to evaluate intravenous CAL02 in addition to standard of care measures in these critical patients, who will be randomized in a 1:1 ratio to either CAL02 or placebo.
- Contact: Alexandra Taylor, 352-294-5481, alexandra.taylor@medicine.ufl.edu
OASIS
- Principal Investigator: Gautam Kalyatanda, MD
- Link: https://clinicaltrials.gov/study/NCT05101187
- Purpose: Aspergillus infection may cause a broad spectrum of diseases in humans, especially those who are immunocompromised. As treatment options can be limited, this study aims to evaluate olorofim as a novel treatment that offers activity against resistant organisms. Patients will be randomized in a 2:1 ratio to receive placebo or olorofim.
- Contact: Tanay Parwal, 314-494-9408, tanay.parwal@medicine.ufl.edu
Closed to Enrollment:
None at this time; please check back soon.
Pending:
None at this time; please check back soon.
Completed:
STOMP
- Principal Investigator: Nicole Iovine, MD, PhD
- Link: https://clinicaltrials.gov/study/NCT05534984
- Purpose: STOMP seeks to evaluate the efficacy of tecovirimat in the treatment of Human Monkeypox Virus Disease by assessing skin and mucosal lesions. Patients will be randomized in a 2:1 ratio to tecovirimat or matching placebo for 14 days.
- Contact: Steve Fowler, 352-294-5277, stevenfowler@ufl.edu
Bravio
- Principal Investigator: Norman Beatty, MD, FACP
- Link: https://clinicaltrials.gov/study/NCT05717062
- Purpose: The treatment of snakebite envenoming has been limited by a lack of access to antivenom therapies. The goal of this study is to evaluate intravenous varespladib followed by oral varespladib in addition to standard of care in subjects bitten by venomous snakes. Patients will be randomized in a 1:1 ratio to receive varespladib or placebo.
- Contact: Tanay Parwal, 314-494-9408, tanay.parwal@medicine.ufl.edu